Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach
Clinical Drug Investigation · 2026-08 · 46 (8) · 897-909
DOI: 10.1007/s40261-026-01569-5 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Drug Investigation, online erschienen am 10.06.2026. Verfasst von Ahmed S Kenawy und 2 weiteren Autor:innen. Beteiligte Einrichtung: Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA. Hauptthemen laut MEDLINE: Hypoglycemic Agents, Prostatic Neoplasms, Diabetes Mellitus, Type 2, Drug Monitoring. Die Arbeit nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA.
- Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, TX, 78712, USA. chanhyun.park@austin.utexas.edu.
Zitieren
APA
Kenawy, A. S., Baffoe, J. O., & Park, C. (2026). Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach. Clinical Drug Investigation, 46(8), 897-909. https://doi.org/10.1007/s40261-026-01569-5
Vancouver
Kenawy AS, Baffoe JO, Park C. Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach. Clinical Drug Investigation. 2026;46(8):897-909. doi:10.1007/s40261-026-01569-5
BibTeX
@article{Kenawy2026,
author = {Kenawy, Ahmed S and Baffoe, James O and Park, Chanhyun},
title = {Change in Adherence to Oral Antidiabetic Medications Before and After Prostate Cancer Diagnosis: A Group-Based Trajectory Modeling Approach},
journal = {Clinical Drug Investigation},
year = {2026},
volume = {46},
number = {8},
pages = {897--909},
doi = {10.1007/s40261-026-01569-5}
}
EUVIMED